Aim Given the impact of vascular comorbidities (VC) on the diagnosis, treatment, and outcome of multiple sclerosis (MS), we examined the incidence and correlation of VC and risk factors for vascular disease in people with MS (PwMS) compared to the general population, and the impact on the physical disability of patients. Methods Cross-sectional study involved 100 patients with MS and 50 healthy people from the general population, matched by sex and age. The values of demographic, biochemical, and anthropometric parameters, the presence of VC and risk factors for vascular diseases in both groups, and clinical parameters in PwMS were analysed. Statistical analysis included methods of descriptive statistics, χ2 test, Student's t-test, analysis of variance, correlation and regression analysis. Results Groups differed by a higher frequency of transient ischemic attack in the control group (p=0.024), and the treatment of hypertension (p=0.038) and smoking frequency (p=0.044) in the MS group. Normal triglycerides levels were statistically significantly more prevalent in the MS group (p=0.000). Total body weight and BMI were statistically significantly higher in the control group (p=0.000). The increase in Expanded Disability Status Scale (EDSS) score was associated with higher levels of total (p=0.001) and low-density lipoprotein (LDL) cholesterol (p=0.003), and activated partial thromboplastin time APTT (p=0.002). Conclusion In PwMS it is necessary to pay attention to the higher frequency of smoking than in general population, and the impact of total cholesterol, LDL and APTT levels as significant parameters that affect physical disability.
Hedström A. Smoking and its interaction with genetics in MS etiology. Mult Scler 2019:180–6.
2
Koudriavtseva T, Stefanile A, Fiorelli M, Lapucci C, Lorenzano S, Zannino S, et al. Coagulation/complement activation and cerebral hypoperfusion in relapsing-remitting multiple sclerosis. Front Immunol 2020:548604.
3
Ziliotto N, Bernardi F, Jakimovski D, Zivadinov R. Coagulation pathways in neurological diseases: multiple sclerosis. Front Neurol 2019:409.
4
Stampanoni B, Iezzi E, Buttari F, Gilio L, Simonelli I, Carbone F, et al. Obesity worsens central inflammation and disability in multiple sclerosis. Mult Scler 2020:1237–46.
5
Jalkh G, Nahed A, Macaron R, Rensel G, M. Safety of newer disease modifying therapies in multiple sclerosis. Vaccines 2020:12.
6
Persson R, Lee S, Yood M, Wagner M, Minton N, Niemcryk S, et al. Multidatabase study of multiple sclerosis: identification, validation and description of MS patients in two countries. J Neurol 2019:1095–106.
7
Palladino R, Marrie R, Majeed A, Chataway J. Evaluating the risk of macrovascular events and mortality among people with multiple sclerosis in England. JAMA Neurol 2020:820–8.
8
Berrigan L, Fisk J, Patten S, Tremlett H, Wolfson C, Warren S, et al. CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS). Healthrelated quality of life in multiple sclerosis: direct and indirect effects of comorbidity. Neurology 2016:1417–24.
9
Moss B, Rensel M, Hersh C. Wellness and the role of comorbidities in multiple sclerosis. Neurotherapeutics 2017:999–1017.
10
Passali M, Josefsen K, Frederiksen J, Antvorskov J. Current evidence on the efficacy of gluten-free diets in multiple sclerosis, psoriasis, type 1 diabetes and autoimmune thyroid diseases. Nutrients 2020:2316.
11
Bang Oturai A, Sellebjerg F, Søndergaard H, Sørensen S, Olsson P, Laursen A, et al. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis. Mult Scler J 2018:1298–305.
12
Auer M, Bsteh G, Hegen H, Pauli D, Wurth F, Berger S, et al. Smoking is not associated with higher prevalence of JC virus in MS patients. Eur J Clin Microbiol Infect Dis 2018:907–10.
13
Arneth B. Multiple Sclerosis and smoking. Am J Med 2020:783–8.
14
Waubant E, Lucas R, Mowry E, Graves J, Olsson T, Alfredsson L, et al. Environmental and genetic risk factors for MS: an integrated review. Ann Clin Transl Neurol 2019:1905–22.
15
Zhang T, Tremlett H, Zhu F, Kingwell E, Fisk J, Bhan V, et al. Effects of physical comorbidities on disability progression in multiple sclerosis. Neurology 2018:419–27.
16
Jakimovski D, Guan Y, Ramanathan M, Weinstock-Guttman B, Zivadinov R. Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings. Neurodegener Dis Manag 2019:149–72.
17
Piluti L, Molti R. Body composition and disability in people with multiple sclerosis. A dual energy x-ray absorptiometry study. Mult Scler Relat Disord 2019:41–7.
18
Ajdacic-Gross V, Steinemann N, Horváth G, Rodgers S, Kaufmann M, Xu Y, et al. Onset symptom clusters in multiple sclerosis: characteristics, comorbidities, and risk factors. Front Neurol 2021:693440.
19
Pašić B, Tudor M, Mustač K, Rajič F, Pašić F, Vujević H, et al. Comorbidities in patients with multiple sclerosis in Croatia. Psychiatr Danub 2021:475–9.
20
Isshiki M, Hirayama S, Ueno T, Ito M, Furuta A, Yano K, et al. Apolipoproteins C-II and C-III as nutritional markers unaffected by inflammation. Clin Chim Acta 2018:225–30.
21
Fellows M, Bhattacharya S, Bodziak M, Jakimovski D, Hagemeier J, Browne R, et al. Oxysterols and apolipoproteins in multiple sclerosis: a 5-year follow-up study. J Lipid Res 2019:1190–8.
22
Kurtzke J. Rating neurologic instrument in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983:1444–52.
23
Arnett D, Blumenthal R, Albert M, Buroker A, Goldberger Z, Hahn E, et al. ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019:140-e596.
24
Diržiuvienė B, Mickevičienė D. Comorbidity in multiple sclerosis: Emphasis on patient-reported outcomes. Mult Scler Relat Disord 2022:103558.
25
Hauer L, Perneczky J, Sellner J. A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications. J Neurol 2021:4066–77.
26
Magyari M, Sorensen P. Comorbidity in multiple sclerosis. Front Neurol 2020:851.
27
Gil-González I, Martín-Rodríguez A, Conrad R, Pérez-San-Gregorio M. Quality of life in adults with multiple sclerosis: a systematic review. BMJ Open 2020:41249.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
